secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2026-07-23T11:14:59+00:00
Accession:  0000105770-26-000097
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q2 net sales up 13.8%, adjusted EPS $2.37 (+28.8%); raises full-year guidance
--------------------------------------------------------------------------------

- Q2 net sales $872.3M (+13.8% reported, +12.7% organic); adjusted-diluted EPS $2.37 (+28.8%).
- Full-year 2026 net sales guidance raised to $3.345B-$3.380B; adjusted EPS guidance raised to $8.85-$9.05.
- HVP Components net sales $424.1M (+19.4%); HVP Delivery Devices $131.2M (+29.6%) driven by Biologics and GLP-1 elastomers.
- Q3 2026 guidance: net sales $820M-$835M, adjusted EPS $2.14-$2.24.
- Repurchased 1.8M shares for $454.3M in H1 2026; declared Q3 dividend $0.22/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/0000105770-26-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000097/wst-20260723.htm
  HTML page:      https://secwatch.observer/filing/0000105770-26-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer